var data={"title":"Thiotepa: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Thiotepa: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7045?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=thiotepa-patient-drug-information\" class=\"drug drug_patient\">see &quot;Thiotepa: Patient drug information&quot;</a> and <a href=\"topic.htm?path=thiotepa-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Thiotepa: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50109503\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myelosuppression:</b> Thiotepa may cause severe marrow suppression, and high doses may cause marrow ablation with resulting infection or bleeding. Monitor hematologic laboratory parameters. Hematopoietic progenitor (stem) cell transplantation is required to prevent potentially fatal complications of the prolonged myelosuppression after high doses of thiotepa.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Carcinogenicity:</b> Thiotepa should be considered potentially carcinogenic in humans.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50047945\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Tepadina</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227204\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Alkylating Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227170\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Thiotepa is associated with a moderate emetic potential in adults (depending on dose/indication); antiemetics may be recommended to prevent nausea and vomiting (Hesketh 2017; Roila 2016). Although included in the manufacturer's labeling as approved uses, other contemporary therapies have replaced the use of thiotepa for the treatment of papillary bladder, ovarian, and breast cancers, as well as malignant intracavitary effusions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hematopoietic</b>\n      <b> stem cell transplant (HSCT) for CNS malignancy (off-label use):</b> IV: 250 mg/m<sup>2</sup>/day for 3 days beginning 9 days prior to transplant (in combination with busulfan and cyclophosphamide) (Soussain 2008) <b>or</b> 150 mg/m<sup>2</sup>/dose every 12 hours for 6 doses, followed by stem cell reinfusion 96 hours after completion of thiotepa (Abrey 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Leptomeningeal metastases (off-label use/route):</b> Intrathecal: 10 mg twice a week (on days 1 and 4 each week) for 8 weeks (Grossman 1993)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10245670\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=thiotepa-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Thiotepa: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> In children, thiotepa is associated with a high emetic potential at doses &ge;300 mg/m<sup>2</sup>; antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Beta-thalassemia, class 3 (Tepadina):</b> Infants, Children, and Adolescents: IV: 5 mg/kg every 12 hours for 2 doses on the sixth day prior to allogeneic hematopoietic stem cell transplantation (in combination with high-dose busulfan and cyclophosphamide)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hematopoietic stem cell transplant (HSCT) for CNS malignancy (off-label use):</b> IV: 300 mg/m<sup>2</sup>/day for 3 days beginning 8 days prior to transplant (in combination with topotecan and carboplatin) (Gilheeney 2010) <b>or</b> 300 mg/m<sup>2</sup>/day for 3 days beginning 5 days prior to transplant (in combination with carboplatin and etoposide) (Dunkel 2010; Grodman 2009)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227171\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227172\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution; decreased renal excretion may result in increased thiotepa and TEPA plasma concentrations and increased toxicity. Monitor patients with moderate (CrCl 30 to 59 mL/minute) to severe (CrCl &lt;30 mL/minute) impairment for toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Thiotepa is dialyzable.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10245671\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution; thiotepa is extensively hepatically metabolized. Moderate (bilirubin &gt;1.5 to 3 times ULN and any AST) or severe (bilirubin &gt;3 times ULN and any AST) impairment may result in increased plasma concentrations and increased toxicity. Monitor closely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20344393\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>American Society for Blood and Marrow Transplantation (ASBMT) practice guideline committee position statement on chemotherapy dosing in obesity:</i> Utilize actual body weight (full weight) for calculation of body surface area in thiotepa dosing for hematopoietic stem cell transplant conditioning regimens in adult patients weighing  &le;120% of their ideal body weight (IBW). In patients weighing &gt;120% IBW, utilize adjusted body weight 40% (ABW40) to calculate BSA (Bubalo 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ABW40: Adjusted wt (kg) = Ideal body weight (kg) + 0.4 [actual wt (kg) - ideal body weight (kg)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10245672\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system toxicity, severe or life-threatening: Discontinue thiotepa and provide supportive care.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity reactions (eg, anaphylaxis or other clinically significant reaction): Discontinue thiotepa and manage as appropriate; monitor until signs/symptoms resolve.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F30124467\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tepadina: 15 mg (1 ea); 100 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tepadina: 15 mg (1 ea); 100 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 15 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227134\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227152\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In children, thiotepa is associated with a high emetic potential at doses &ge;300 mg/m<sup>2</sup> (Dupuis 2011) and is associated with a moderate emetic potential (depending on dose/indication) in adults (Hesketh 2017; Roila 2016). antiemetics may be recommended to prevent nausea and vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Administer over 3 hours via a central line (when administering as part of the preparative regimen for hematopoietic stem cell transplantation in class 3 beta-thalassemia). Infusion times may vary by protocol or dose for off-label uses; refer to specific protocols. Filtering does not alter thiotepa potency. <i>Tepadina:</i> Administer using a 0.2 micron in-line filter; flush line prior to and after infusion with ~5 mL NS.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intrathecal route (off-label use/route): Was administered in 10 mL (preservative free) buffered solutions (Grossman 1993)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132739\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227150\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Beta-thalassemia, class 3:</b> To reduce the risk of graft rejection when used in conjunction with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation in pediatric patients with class 3 beta-thalassemia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49210592\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Hematopoietic stem cell transplant (HSCT) for CNS malignancy; Leptomeningeal metastases (intrathecal)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3402289\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Thiotepa may be confused with thioguanine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">\n          <i>Intrathecal medication safety:</i> The American Society of Clinical Oncology (ASCO)/Oncology Nursing Society (ONS) chemotherapy administration safety standards (Jacobson 2009) encourage the following safety measures for intrathecal chemotherapy:</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">&bull; Intrathecal medication should not be prepared during the preparation of any other agents</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">&bull; After preparation, keep in an isolated location or container clearly marked with a label identifying as &quot;intrathecal&quot; use only</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">&bull; Delivery to the patient should only be with other medications also intended for administration into the central nervous system</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227141\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">As a preparative regimen prior to allogeneic or autologous hemtopoietic progenitor cell transplantation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Intracranial hemorrhage, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Mucositis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hematologic &amp; oncologic: Anemia, hemorrhage, neutropenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hepatic: Increased serum ALT, increased serum AST, increased serum bilirubin</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infection: Cytomegalovirus disease</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Respiratory: Pneumonia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Other approved/nonapproved uses:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Dermatologic: Alopecia, contact dermatitis, dermatitis, skin depigmentation, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Central nervous system: Dizziness, fatigue, headache</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Endocrine &amp; metabolic: Amenorrhea</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Gastrointestinal: Abdominal pain, anorexia, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Genitourinary: Cystitis, dysuria, hemorrhagic cystitis, inhibition of Spermatogenesis, urinary retention</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hypersensitivity: Anaphylactic shock, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Local: Pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Neuromuscular &amp; skeletal: Weakness</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Ophthalmic: Blurred vision, conjunctivitis</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Respiratory: Asthma, laryngeal edema, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Miscellaneous: Febrile reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal gait, acute myelocytic leukemia, acute respiratory distress, acute sinusitis, amnesia, apathy, aphasia, arteriosclerosis (pulmonary arteriopathy), ascites, aspiration, ataxia, behavioral problems, blepharoptosis, blindness, blood coagulation disorder, blood platelet disorder (refractoriness to transfusion), bone marrow aplasia, bone marrow depression (bone marrow transplant rejection), bradycardia, brain disease, candidiasis, capillary leak syndrome, cardiac failure, cerebrovascular accident, cognitive dysfunction, coma, confusion, cranial nerve palsy, deafness, delirium, depression, diarrhea, disorientation, drowsiness, dysphagia, dyspnea on exertion, encephalitis, enterocolitis, epstein-barr infection, fever, forgetfulness, fungal infection, gastritis, gastroenteritis, gastrointestinal hemorrhage, hallucination, hematuria, hemiplegia, hepatomegaly, hyponatremia, hypotonia, immunosuppression, infection due to enterococcus, interstitial pulmonary disease, klebsiella species, lesion (including central nervous system and white matter), leukemia (recurrent), leukoencephalopathy, lower respiratory tract infection (viral), lymphoproliferative disorder (posttransplant), malaise, malignant lymphoma (including central nervous system lymphoma), malignant neoplasm (recurrence), malignant neoplasm of breast (metastatic), memory impairment, motor dysfunction, mouth disease (palatal disorder), myelodysplastic syndrome, neoplasm (metastatic), neurotoxicity, pain, papilledema, paralysis (retrobulbar), paresis (quadriparesis), pericardial effusion, pericarditis, pneumonitis, pseudomonas infection, psychomotor retardation, pulmonary aspergillosis, pulmonary disease, pulmonary hypertension, pulmonary veno-occlusive disease, pure red cell aplasia, renal failure, respiratory distress, respiratory tract infection, sepsis, septic shock, speech disturbance, staphylococcal bacteremia, staphylococcal infection, Stevens-Johnson Syndrome, strabismus, subarachnoid hemorrhage, subdural hematoma, suicidal ideation, thrombotic thrombocytopenic purpura (cerebral), toxic epidermal necrolysis, toxic nephrosis, tremor, urinary tract infection, vasodilatation (cerebral ventricle), ventricular hypertrophy, weight gain</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227155\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Known hypersensitivity (allergy) to thiotepa or any component of the formulation; concomitant use with live or attenuated vaccines (Tepadina)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227138\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Myelosuppression (leukopenia, thrombocytopenia, and anemia) may commonly occur, particularly when used as part of the preparative regimen for hematopoietic stem cell transplantation (HSCT) or in patients with compromised bone marrow function. Do not initiate the HSCT conditioning regimen if a stem cell donor is not available. Monitor blood counts closely. Monitor for infection or bleeding; death due to septicemia and hemorrhage has occurred. Myelosuppression (including fatal cases) has also been reported with intravesicular administration (due to systemic absorption).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Fatal encephalopathy has been reported in patients receiving high-dose thiotepa. Headache, apathy, psychomotor retardation, disorientation, confusion, amnesia, hallucinations, drowsiness, somnolence, seizures, coma, inappropriate behavior, and forgetfulness have also been reported (may be dose dependent). If severe or life-threatening central nervous system toxicity occurs, discontinue treatment and manage as necessary. CNS toxicity, including seizures and intracranial hemorrhage was reported in pediatric patients who receive the recommended dose in combination with busulfan and cyclophosphamide as a stem cell conditioning regimen for beta thalassemia; do not exceed the recommended dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic toxicity: In patients receiving high-dose thiotepa, the parent drug and/or its active metabolites may be partially excreted through the skin. Thiotepa may cause skin discoloration, pruritus, blistering, desquamation, and peeling (may be more severe in skin folds, groin, axillae, and neck areas, and under dressings). Change occlusive dressing and clean covered skin at least twice daily during and for 48 hours after thiotepa administration (when used as a component of the HSCT preparative regimen). Patients should shower/bathe in water twice daily through 48 hours after receiving thiotepa. Change bed sheets daily. Accidental thiotepa exposure is also associated with skin reactions; wash skin thoroughly with soap and water and flush mucous membranes if skin and/or mucous membrane contact occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI toxicity: In children, thiotepa is associated with a high emetic potential at doses &ge;300 mg/m<sup>2</sup> (Dupuis 2011) and is associated with a moderate emetic potential (depending on dose/indication) in adults (Hesketh 2017; Roila 2016); antiemetics are recommended to prevent nausea and vomiting. Thiotepa is also associated with mucositis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic sinusoidal obstruction syndrome: Hepatic sinusoidal obstruction syndrome (SOS, also called veno-occlusive disease [VOD]) may occur in patients receiving thiotepa in combination with busulfan and cyclophosphamide as a preparative regimen prior to HSCT. Monitor serum transaminases, bilirubin and for signs/symptoms of hepatic SOS through day +28 of stem cell transplant; provide supportive care if SOS develops.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Clinically significant hypersensitivity reactions (including anaphylaxis) have occurred. If an anaphylactic or other clinically significant hypersensitivity reaction occurs, discontinue thiotepa treatment and initiate appropriate supportive management. Monitor until resolution of symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary malignancies: Thiotepa is potentially carcinogenic; myelodysplastic syndrome and acute myeloid leukemia (AML) have been reported. There is an increased risk of secondary malignancies with thiotepa use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; thiotepa is extensively hepatically metabolized; moderate (bilirubin &gt;1.5 to 3 times ULN and any AST) or severe (bilirubin &gt;3 times ULN and any AST) impairment may result in increased plasma concentrations and increased toxicity. Monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; decreased renal excretion may result in increased thiotepa and TEPA plasma concentrations and increased toxicity. Monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: Do not administer live or attenuated viral or bacterial vaccines until the immunosuppressive effects of thiotepa have resolved.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intrathecal safety: When used for intrathecal administration (off-label route), should not be prepared during the preparation of any other agents. After preparation, keep intrathecal medications in an isolated location or container clearly marked with a label identifying as &quot;intrathecal&quot; use only. Delivery of intrathecal medications to the patient should only be with other medications also intended for administration into the central nervous system (Jacobson 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227199\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227143\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9992&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2B6 Substrates (High risk with Inhibitors): Thiotepa may increase the serum concentration of CYP2B6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227145\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3881813\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Based on the mechanism of action, thiotepa may cause fetal harm if used in pregnant women. Verify pregnancy status in women of reproductive potential prior to therapy initiation. Effective contraception should be used during treatment and for at least 6 months after the final dose. Males with female partners of reproductive potential should use effective contraception during therapy and for at least 1 year after the final dose. Both male and female fertility may be affected by thiotepa administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10245667\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if thiotepa is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227147\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelet count frequently throughout therapy; renal and liver function tests; signs/symptoms of hypersensitivity reactions, dermatologic toxicity, hepatic sinusoidal obstruction syndrome, and CNS toxicity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227137\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Thiotepa is an alkylating agent which produces cross-linking of DNA strands leading to inhibition of DNA, RNA, and protein synthesis; thiotepa is cell-cycle independent (Perry 2012)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227154\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: 0.3 to 1.6 L/kg; penetrates into CSF (Maanen 2000); the mean volume of distribution following a single IV dose in pediatric patients receiving a 5 mg/kg dose was 1.2 L/kg or 30 L/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~10% to 20%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensively hepatic via cytochrome P450 system, primarily to the major (active) metabolite TEPA (Maanen 2000; Perry 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Terminal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatrics (5 mg/kg IV dose): Thiotepa: 1.7 hours; TEPA: 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults (20 mg to 250 mg/m<sup>2</sup> IV dose): Thiotepa: 1.4 to 3.7 hours; TEPA: 4.9 to 17.6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (&lt;2% of thiotepa dose; &lt;11% of TEPA)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323960\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Tepadina Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (1): $1,080.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $5,640.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Thiotepa Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (1): $1,680.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038841\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ledertepa (BE, LU, NL);</li>\n      <li>Oncotiotepa (BE, LU);</li>\n      <li>Tepadina (BB, CZ, ES, FR, GB, HK, HR, HU, IE, KR, MT, NO, PL, TR);</li>\n      <li>Tespamin (JP, TW);</li>\n      <li>Thio-Tepa (AR, CZ);</li>\n      <li>Thiooplex (GR, IT);</li>\n      <li>Thiotepa Lederle (AT, CH, DE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16524945\"></a>Abrey LE, Childs BH, Paleologos N, et al. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. <i>Neuro Oncol</i>. 2006;8(2):183-188.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thiotepa-drug-information/abstract-text/16524945/pubmed\" target=\"_blank\" id=\"16524945\">16524945</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bubalo J, Carpenter PA, Majhail N, et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. <i>Biol Blood Marrow Transplant</i>. 2014;20(5):600-616.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thiotepa-drug-information/abstract-text/24462742/pubmed\" target=\"_blank\" id=\"24462742\">24462742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DeAngelis LM and Butros D, &ldquo;Leptomeningeal Metastasis,&rdquo; <i>Cancer Invest</i>, 2005, 23(2):145-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thiotepa-drug-information/abstract-text/15813508/pubmed\" target=\"_blank\" id=\"15813508\">15813508</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Lemos ML, Monfared S, Denyssevych T, et al, &ldquo;Evaluation of Osmolality and pH of Various Concentrations of Methotrexate, Cytarabine, and Thiotepa Prepared in Normal Saline, Sterile Water for Injection, and Lactated Ringer's Solution for Intrathecal Administration,&rdquo; <i>J Oncol Pharm Pract</i>, 2009, 15(1):45-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thiotepa-drug-information/abstract-text/18772215 /pubmed\" target=\"_blank\" id=\"18772215 \">18772215 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20167818\"></a>Dunkel IJ, Gardner SL, Garvin JH Jr, et al, &ldquo;High-Dose Carboplatin, Thiotepa, and Etoposide With Autologous Stem Cell Rescue for Patients With Previously Irradiated Recurrent Medulloblastoma,&rdquo; <i>Neuro Oncol</i>, 2010, 12(3):297-303.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thiotepa-drug-information/abstract-text/20167818/pubmed\" target=\"_blank\" id=\"20167818\">20167818</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al. Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thiotepa-drug-information/abstract-text/23512831/pubmed\" target=\"_blank\" id=\"23512831\">23512831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21465637\"></a>Dupuis LL, Boodhan S, Sung L, et al. Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thiotepa-drug-information/abstract-text/23512831/pubmed\" target=\"_blank\" id=\"23512831\">23512831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19998470\"></a>Gilheeney SW, Khakoo Y, Souweidane M, et al. Thiotepa/Topotecan/Carboplatin With Autologous Stem Cell Rescue in Recurrent/Refractory/Poor Prognosis Pediatric Malignancies of the Central Nervous System. <i>Pediatr Blood Cancer.</i> 2010;54(4):591-595.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thiotepa-drug-information/abstract-text/19998470/pubmed\" target=\"_blank\" id=\"19998470\">19998470</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19326417\"></a>Grodman H, Wolfe L, and Kretschmar C, &ldquo;Outcome of Patients With Recurrent Medulloblastoma or Central Nervous System Germinoma Treated With Low Dose Continuous Intravenous Etoposide Along With Dose-Intensive Chemotherapy Followed by Autologous Hematopoietic Stem Cell Rescue,&rdquo; <i>Pediatr Blood Cancer</i>, 2009, 53(1):33-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thiotepa-drug-information/abstract-text/19326417/pubmed\" target=\"_blank\" id=\"19326417\">19326417</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8445432\"></a>Grossman SA, Finkelstein DM, Ruckeschel JC, et al, &ldquo;Randomized Prospective Comparison of Intraventricular Methotrexate and Thiotepa in Patients With Previously Untreated Neoplastic Meningitis. Eastern Cooperative Oncology Group,&rdquo; <i>J Clin Oncol</i>, 1993, 11(3):561-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thiotepa-drug-information/abstract-text/8445432/pubmed\" target=\"_blank\" id=\"8445432\">8445432</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2017;35(28):3240-3261. doi: 10.1200/JCO.2017.74.4789.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thiotepa-drug-information/abstract-text/28759346/pubmed\" target=\"_blank\" id=\"28759346\">28759346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobson JO, Polovich M, McNiff KK, et al, &quot;American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards,&quot; <i>J Clin Oncol</i>, 2009, 27(32):5469-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thiotepa-drug-information/abstract-text/19786650/pubmed\" target=\"_blank\" id=\"19786650\">19786650</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maanen MJ, Smeets CJ, and Beijnen JH, &ldquo;Chemistry, Pharmacology and Pharmacokinetics of N,N',N&quot;, -Triethylenethiophosphoramide (ThioTEPA),&quot; <i>Cancer Treat Rev</i>, 2000, 26(4):257-68.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perry MC. Chemotherapeutic agents: Thiotepa. <i>The Chemotherapy Source Book</i>. 5th ed. Philadelphia, PA: 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133. doi: 10.1093/annonc/mdw270.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thiotepa-drug-information/abstract-text/27664248/pubmed\" target=\"_blank\" id=\"27664248\">27664248</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18413641\"></a>Soussain C, Hoang-Xuan K, Taillandier L, et al, &ldquo;Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Soci&eacute;t&eacute; Fran&ccedil;aise de Greffe de Mo&euml;lle Osseuse-Th&eacute;rapie Cellulaire,&rdquo; <i>J Clin Oncol</i>, 2008, 26(15):2512-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thiotepa-drug-information/abstract-text/18413641/pubmed\" target=\"_blank\" id=\"18413641\">18413641</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tepadina (thiotepa) [prescribing information]. Bridgewater, NJ: Amneal Biosciences LLC; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thiotepa [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; February 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9992 Version 142.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F50109503\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F50047945\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F227204\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F227170\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F10245670\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F227171\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F227172\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F10245671\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20344393\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F10245672\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F30124467\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F227134\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F227152\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132739\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F227150\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F49210592\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3402289\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F227141\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F227155\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F227138\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F227199\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F227143\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F227145\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3881813\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F10245667\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F227147\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F227137\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F227154\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323960\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038841\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9992|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=thiotepa-patient-drug-information\" class=\"drug drug_patient\">Thiotepa: Patient drug information</a></li><li><a href=\"topic.htm?path=thiotepa-pediatric-drug-information\" class=\"drug drug_pediatric\">Thiotepa: Pediatric drug information</a></li></ul></div></div>","javascript":null}